Goiter: What Could Be Causing It

What Is a Goiter?

A goiter refers to any abnormal enlargement of the thyroid gland, the butterfly-shaped organ at the base of the neck that produces hormones controlling metabolism, heart rate, and body temperature. The normal adult thyroid weighs between 15 and 25 grams. When it grows beyond that range, whether diffusely or with distinct nodules, clinicians call it a goiter.

Diffuse vs. Nodular

Goiters fall into two broad morphologic categories. A diffuse goiter involves uniform enlargement of the entire gland. A nodular goiter contains one or more discrete lumps within the thyroid tissue. Multinodular goiters (MNG) are especially common in older adults. The American Thyroid Association (ATA) 2015 guidelines note that thyroid nodules are detectable by ultrasound in up to 68% of the general population, though most are benign and clinically insignificant.

Functional Classification

Thyroid function at the time of diagnosis matters. A goiter can present alongside hypothyroidism (as in Hashimoto's), hyperthyroidism (as in Graves' disease or toxic multinodular goiter), or completely normal thyroid hormone levels (euthyroid goiter). The functional status shapes treatment decisions directly.

The distinction between a goiter that is simply large and one that is producing too much or too little hormone changes the clinical urgency. A small euthyroid goiter may need nothing more than monitoring. A rapidly growing goiter with compressive symptoms requires imaging and possibly surgery within weeks.

Iodine Deficiency: The Global Leader

Worldwide, inadequate dietary iodine remains the single most common cause of goiter. The thyroid requires iodine to synthesize thyroxine (T4) and triiodothyronine (T3). When iodine intake drops below roughly 50 micrograms per day, the pituitary releases more TSH, which drives thyroid cell proliferation and gland enlargement as a compensatory mechanism.

Epidemiology

The World Health Organization estimates that approximately 1.6 billion people live in areas of iodine deficiency. Endemic goiter (prevalence above 5% in school-age children) persists in parts of Sub-Saharan Africa, Southeast Asia, and Central Asia. Universal salt iodization programs have reduced but not eliminated the problem.

The U.S. Context

In the United States, iodine deficiency goiter became rare after mandatory salt iodization began in the 1920s. The median urinary iodine concentration in U.S. Adults is approximately 144 µg/L, which falls within the WHO-defined adequate range of 100 to 199 µg/L [1]. Still, subgroups remain at risk. Pregnant women have higher iodine requirements (250 µg/day), and NHANES data show that roughly one-third of U.S. Pregnant women have urinary iodine levels below the adequacy threshold.

People who avoid iodized salt, follow restrictive diets, or consume large amounts of goitrogenic foods (raw cruciferous vegetables, cassava, soy) without adequate iodine compensation may develop subclinical deficiency that manifests as gradual thyroid enlargement over months to years.

Hashimoto's Thyroiditis

Hashimoto's thyroiditis (chronic lymphocytic thyroiditis) is the most common cause of goiter in iodine-sufficient populations. It is an autoimmune condition in which the immune system attacks thyroid tissue, triggering inflammation, lymphocytic infiltration, and progressive destruction of thyroid follicular cells.

Mechanism of Enlargement

The gland enlarges due to lymphocytic infiltration and fibrosis rather than true follicular hyperplasia. Over time, the destructive process typically leads to hypothyroidism, although patients may be euthyroid for years before TSH begins to rise. A study published in The Journal of Clinical Endocrinology & Metabolism reported that the annual rate of progression from subclinical to overt hypothyroidism in TPOAb-positive individuals is approximately 4.3%.

Who Gets It

Hashimoto's affects women roughly 5 to 10 times more often than men. Peak onset occurs between ages 30 and 50. Family history of autoimmune thyroid disease is a strong risk factor. The goiter in Hashimoto's is typically firm, diffuse, and nontender, though it can become nodular over time. Elevated anti-TPO antibodies confirm the diagnosis in more than 90% of cases [2].

Lab Pattern

The classic Hashimoto's lab profile shows elevated TSH, low or low-normal free T4, and positive TPO antibodies. Early in the disease, TSH may be normal while antibodies are already elevated, a phase called "euthyroid autoimmune thyroiditis."

Graves' Disease

Graves' disease is the leading cause of hyperthyroidism and the second most common autoimmune cause of goiter. Thyroid-stimulating immunoglobulins (TSI) bind the TSH receptor and drive unregulated hormone production, causing the gland to enlarge diffusely.

Clinical Features

The goiter in Graves' disease is characteristically diffuse, smooth, and sometimes accompanied by a bruit (audible on stethoscope due to increased blood flow). Patients present with heat intolerance, weight loss, tremor, palpitations, and sometimes Graves' ophthalmopathy. The National Institute of Diabetes and Digestive and Kidney Diseases notes that Graves' disease affects roughly 1 in 200 people in the U.S., with a strong female predominance (7:1 female-to-male ratio).

Diagnosis

TSH is suppressed (often <0.01 mIU/L), free T4 and/or free T3 are elevated, and TSI or thyroid-stimulating antibody (TSAb) levels are positive in more than 95% of patients. Radioactive iodine uptake (RAIU) testing shows diffusely increased uptake, which distinguishes Graves' from thyroiditis-induced thyrotoxicosis where uptake is low.

Treatment and Goiter Resolution

Treatment options include antithyroid drugs (methimazole, propylthiouracil), radioactive iodine ablation, or thyroidectomy. The goiter often shrinks substantially with methimazole therapy. A Cochrane review found that antithyroid drugs achieve remission in 40 to 60% of patients after 12 to 18 months, with lower relapse rates in patients whose goiter size normalizes during treatment.

Multinodular Goiter

A multinodular goiter (MNG) contains two or more discrete nodules within an enlarged thyroid. It is extremely common, especially in women over 50. Most MNGs are nontoxic (euthyroid), but a subset becomes autonomous, producing excess thyroid hormone without TSH stimulation. That condition is called toxic multinodular goiter (Plummer disease).

Natural History

MNG tends to grow slowly over decades. The ATA guidelines recommend ultrasound evaluation of all palpable nodules and any nodule discovered incidentally on imaging. Nodules 1 cm or larger with suspicious ultrasound characteristics (hypoechogenicity, microcalcifications, irregular margins, taller-than-wide shape) warrant fine-needle aspiration (FNA) biopsy to exclude malignancy.

Malignancy Risk

The rate of thyroid cancer within a multinodular goiter is roughly 5 to 15%, comparable to the malignancy rate in solitary nodules [3]. This finding, established in large surgical series published in Archives of Surgery and corroborated by subsequent studies, eliminated the older assumption that multinodularity was inherently "safe."

Compressive Symptoms

Large MNGs can compress the trachea, esophagus, or recurrent laryngeal nerve. Symptoms include dyspnea (especially when lying flat or raising arms overhead, known as Pemberton's sign), dysphagia, hoarseness, or a sensation of neck pressure. Substernal extension occurs in 5 to 15% of cases and may require cross-sectional imaging (CT without iodinated contrast, to avoid iodine loading) for surgical planning.

Thyroiditis: Subacute, Postpartum, and Silent

Several inflammatory thyroid conditions cause transient goiter. These are frequently misdiagnosed because they can mimic both hyper- and hypothyroid states at different phases.

Subacute (de Quervain's) Thyroiditis

This granulomatous thyroiditis follows a viral upper respiratory infection in many cases. The thyroid becomes painful, tender, and enlarged. Patients often present with thyrotoxic symptoms during the initial destructive phase (lasting 2 to 8 weeks), followed by a hypothyroid phase, and then recovery. ESR is markedly elevated. A study in Thyroid documented that 90 to 95% of patients fully recover normal thyroid function within 6 to 12 months without specific treatment beyond NSAIDs or short-course corticosteroids.

Postpartum Thyroiditis

Postpartum thyroiditis affects 5 to 10% of women within 12 months of delivery. It is essentially a flare of underlying autoimmune thyroiditis triggered by the immune rebound after pregnancy. The goiter is usually mild. Like subacute thyroiditis, it often follows a biphasic pattern (thyrotoxicosis, then hypothyroidism), but up to 25% of affected women develop permanent hypothyroidism [4].

Silent (Painless) Thyroiditis

Silent thyroiditis presents identically to postpartum thyroiditis but occurs outside the postpartum period. It is autoimmune in origin, associated with positive TPO antibodies, and typically self-limited. The goiter is modest and nontender.

Less Common Causes

Drug-Induced Goiter

Several medications can cause thyroid enlargement. Lithium, used in bipolar disorder, inhibits thyroid hormone release and causes goiter in up to 50% of long-term users, according to a review in The Journal of Clinical Psychiatry. Amiodarone, an iodine-rich antiarrhythmic, can cause either hypothyroidism or thyrotoxicosis with goiter. Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) cause thyroiditis in 5 to 10% of treated patients.

Thyroid Cancer

Thyroid malignancy can present as a goiter, particularly when a dominant nodule grows rapidly. Papillary thyroid carcinoma accounts for roughly 80% of thyroid cancers. The National Cancer Institute SEER database reports that the incidence of thyroid cancer tripled between 1975 and 2015 (from 4.9 to 14.4 per 100,000), largely driven by increased detection of small papillary carcinomas through imaging. Red flags that raise concern for malignancy include rapid nodule growth, fixation to adjacent structures, vocal cord paralysis, and ipsilateral lymphadenopathy.

Infiltrative Disorders

Rare causes of goiter include amyloidosis, sarcoidosis, hemochromatosis, and Riedel's thyroiditis (a fibrosing variant that creates a rock-hard, fixed gland). These typically present with distinctive features on physical exam and imaging that prompt biopsy.

Congenital Goiter

Neonatal goiter can result from maternal iodine deficiency, maternal antithyroid drug use, or inborn errors of thyroid hormone synthesis (dyshormonogenesis). These are uncommon in developed countries but remain a significant cause of preventable intellectual disability globally.

Diagnostic Workup

The evaluation of a goiter follows a structured approach designed to identify the cause, assess thyroid function, and rule out malignancy.

Step 1: Serum TSH

TSH is the single most informative initial test. A normal TSH suggests euthyroid goiter. Elevated TSH points toward Hashimoto's or iodine deficiency. Suppressed TSH suggests Graves' disease or toxic nodular goiter. The ATA and American Association of Clinical Endocrinology (AACE) both endorse TSH as the mandatory first step.

Step 2: Thyroid Antibodies and Additional Labs

If TSH is elevated, check free T4 and anti-TPO antibodies. If TSH is suppressed, check free T4, free T3, and TSI/TSAb. Thyroglobulin levels are not useful for initial goiter evaluation but become relevant in thyroid cancer surveillance after thyroidectomy.

Step 3: Thyroid Ultrasound

Ultrasound characterizes the gland architecture, measures volume, counts and describes nodules, and evaluates cervical lymph nodes. The ACR Thyroid Imaging, Reporting and Data System (TI-RADS) assigns risk scores to nodules based on composition, echogenicity, shape, margins, and echogenic foci. Nodules scoring TR4 or TR5 are recommended for FNA at size thresholds of ≥1.5 cm and ≥1 cm, respectively [5].

Step 4: Fine-Needle Aspiration

FNA cytology remains the gold standard for distinguishing benign from malignant nodules. Results are reported using the Bethesda System for Reporting Thyroid Cytopathology, which assigns a category (I through VI) with an associated malignancy risk ranging from 1 to 4% (Bethesda II, benign) to 97 to 99% (Bethesda VI, malignant). Molecular testing (Afirma, ThyroSeq) can help triage indeterminate results (Bethesda III, IV).

Step 5: Radioactive Iodine Uptake (When Indicated)

RAIU is reserved for patients with suppressed TSH to differentiate Graves' disease (diffusely increased uptake) from toxic adenoma (focal uptake) or thyroiditis (low uptake). It is not part of routine goiter evaluation in euthyroid patients.

Treatment by Cause

Treatment is not "for goiter" generically. It targets the underlying condition driving thyroid enlargement.

Iodine Deficiency

Iodine supplementation (150 to 250 µg daily for adults, higher in pregnancy) corrects the deficiency. In established endemic goiter, levothyroxine suppression therapy was historically used but is no longer routinely recommended due to limited efficacy and risk of iatrogenic hyperthyroidism in older patients with autonomous nodules.

Hashimoto's Thyroiditis

Levothyroxine replacement is indicated once TSH rises above the reference range (typically >4.5 mIU/L) or symptoms of hypothyroidism develop. The 2014 ATA guidelines for hypothyroidism recommend a starting dose of 1.6 µg/kg/day in otherwise healthy adults, with dose titration every 6 to 8 weeks to target a TSH of 0.5 to 2.5 mIU/L. Goiter size often decreases over 6 to 12 months on adequate replacement.

Graves' Disease

First-line treatment varies by geography. In the U.S., radioactive iodine ablation has been the traditional preference, while European and Asian guidelines tend to favor antithyroid drugs first. Methimazole 10 to 30 mg daily is preferred over propylthiouracil (except in the first trimester of pregnancy) due to a better safety profile [6].

Toxic or Compressive Multinodular Goiter

Surgery (total or near-total thyroidectomy) is the treatment of choice for MNG causing compressive symptoms, cosmetic concern, or suspected malignancy. Radioactive iodine is an alternative for toxic MNG in patients who are poor surgical candidates. A randomized trial published in the Journal of Clinical Endocrinology & Metabolism found that recombinant TSH-stimulated radioiodine therapy reduced goiter volume by a median of 55% at 12 months in large nontoxic MNG.

Thyroid Cancer

Management follows risk-stratified guidelines from the ATA 2015 thyroid cancer management guidelines. Low-risk papillary microcarcinomas (<1 cm, confined to the thyroid) may be candidates for active surveillance rather than immediate surgery. Higher-risk tumors require total thyroidectomy, sometimes followed by radioactive iodine remnant ablation and TSH suppression with levothyroxine.

When to See a Doctor

Not every goiter is urgent, but certain features warrant prompt evaluation. Seek medical attention if you notice rapid enlargement over days to weeks, difficulty swallowing or breathing, persistent hoarseness, a hard or fixed neck mass, or associated weight loss with a racing heart. A goiter discovered incidentally on imaging (CT, MRI, carotid ultrasound) still needs thyroid-specific workup with TSH and dedicated thyroid ultrasound.

Routine goiter monitoring typically involves annual TSH and periodic ultrasound. The interval depends on baseline findings: stable euthyroid goiters without suspicious nodules can be re-imaged every 12 to 24 months, while nodules with indeterminate cytology may require repeat FNA or molecular testing within 6 to 12 months per AACE/ACR recommendations.

Patients with goiter and suppressed TSH should be evaluated before any contrast-enhanced CT scan, as iodinated contrast agents can precipitate thyroid storm in patients with underlying autonomous thyroid tissue.